Staar Surgical Company Stock News

The FDA approved the company's EVO implantable lens for nearsightedness.

We present 2 sample Breakout Stocks for Week 12 with better than 10% short-term upside potential and a Dow stock pick. Click here to know them.

Two sample Breakout Stocks for Week 12 with better than 10% short-term upside potential and a Dow stock pick.

BTIG upgraded Implantable lenses-focused Staar Surgical Company (NASDAQ: STAA) to Buy from Neutral with a $98 price target.  Analyst Ryan Zimmerman believes that the Company's fundamentals will li

BTIG upgraded Implantable lenses-focused Staar Surgical Company (NASDAQ: STAA) to Buy from Neutral with a $98 price target.  Analyst Ryan Zimmerman believes that the Company's fundamentals will li

Upgrades For United Airlines Holdings Inc (NASDAQ:UAL), Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. United Airlines Holdings earned $1.60 in the fourth quarter, compare

These stocks make great pillars to help solidify your portfolio.

STAAR Surgical <> stock rose following its earnings results, where Q4 net sales grew 28% Y/Y to $59M.The company said the increase was driven by ICL sales and unit growth of 33%…

Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical Company's (STAA) CEO Caren Mason on Q4 2021 Results - Earnings Call Transcript

STAAR Surgical press release (NASDAQ:STAA): Q4 Non-GAAP EPS of $0.19 beats by $0.03.Revenue of $59M (+28.3% Y/Y) misses by $0.21M.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Overview Net Sales of $59.0 Million Up 28% from the Prior Year Quarter ICL Sales of $53.0 Million Up 33% from the Prior Year Quarter ICL Units Up 36% from the Prior Year Quarter Gross Margin a

Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical (NASDAQ:STAA) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, after market close.The consensus EPS Estimate is $0.16 (+14.3% Y/Y) and the